Drug profile · INN
umbralisib tosylate
UKONIQ
umbralisib tosylate (UKONIQ) is a tyrosine-protein kinase abl inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — umbralisib tosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
umbralisib tosylate (UKONIQ) is a tyrosine-protein kinase abl inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase ABL inhibitor
Primary target: Casein kinase I isoform epsilon
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is umbralisib tosylate?
umbralisib tosylate (UKONIQ) is a tyrosine-protein kinase abl inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for umbralisib tosylate?
UKONIQ is a marketed brand name for umbralisib tosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of umbralisib tosylate?
umbralisib tosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.